+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Exosomes, CTC), Application (Cancer, Reproductive Health), Technology, Sample Type, Clinical Application, End-use, Product, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 4582091
The global Liquid Biopsy Market size was valued at USD 22.88 billion in 2030 and is expected to expand at a compound annual growth rate (CAGR) of 9.7% from 2023 to 2030. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former’s HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

Liquid Biopsy Market Report Highlights

  • The ctDNA segment is projected to hold the largest share in the market owing to its wide use as a biomarker in the detection of cancer using liquid biopsy
  • The multi-gene-parallel analysis (NGS) technology segment is expected to grow lucratively due to increasing research and development, increasing cancer cases, advancements in technology, and strategic activities by leading companies
  • North America dominated the global market in 2022, owing to the increasing demand for new technologies, a large pool of key players, the presence of several clinical laboratories, and advanced healthcare infrastructure in the region
  • Asia-Pacific is expected to grow considerably in the future, owing to the rising prevalence of target conditions in the region and the presence of key players


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List Of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing prevalence of cancer
3.4.2. Growing geriatric population
3.4.3. Technological advancements
3.4.4. Increasing preference for noninvasive treatment
3.5. Market Restraint Analysis
3.5.1. Patent expiry of blockbuster drugs prescribed
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Liquid Biopsy Market: Type Movement Analysis
4.2. Blood Sample
4.2.1. Blood Sample Market, 2018-2030 (USD Million)
4.3. Others
4.3.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Biomarker Business Analysis
5.1. Liquid Biopsy Market: Biomarker Movement Analysis
5.2. Circulating Tumor Cells (CTCs)
5.2.1. Circulating Tumor Cells (CTCs) Market, 2018-2030 (USD Million)
5.3. Circulating Tumor DNA (catena)
5.3.1. Circulating Nucleic Acids Market, 2018-2030 (USD Million)
5.4. Exosomes/Microvesicles
5.4.1. Exosomes/Microvesicles Market, 2018-2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Technology Business Analysis
6.1. Liquid Biopsy Market: Technology Movement Analysis
6.2. Multi-gene-parallel Analysis (NGS)
6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2018-2030 (USD Million)
6.3. Single Gene Analysis (PCR Microarrays)
6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2018-2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Liquid Biopsy Market: Application Movement Analysis
7.2. Cancer
7.2.1. Cancer Market, 2018-2030 (USD Million)
7.2.1.1. Lung Cancer
7.2.1.2. Lung Cancer Market, 2018-2030 (USD Million)
7.2.1.3. Prostate Cancer
7.2.1.4. Prostate Cancer Market, 2018-2030 (USD Million)
7.2.1.5. Breast Cancer
7.2.1.6. Breast Cancer Market, 2018-2030 (USD Million)
7.2.1.7. Colorectal Cancer
7.2.1.8. Colorectal Cancer Market, 2018-2030 (USD Million)
7.2.1.9. Leukemia
7.2.1.10. Leukemia Market, 2018-2030 (USD Million)
7.2.1.11. Gastrointestinal Cancer
7.2.1.12. Gastrointestinal Cancer Market, 2018-2030 (USD Million)
7.2.1.13. Others
7.2.1.14. Others Market, 2018-2030 (USD Million)
7.3. Reproductive Health
7.3.1. Reproductive Health Market, 2018-2030 (USD Million)
7.4. Others
7.4.1. Others Market, 2018-2030 (USD Million)
Chapter 8. End-Use Business Analysis
8.1. Liquid Biopsy Market: End-Use Movement Analysis
8.2. Hospitals and Laboratories
8.2.1. Hospitals and Laboratories Market, 2018-2030 (USD Million)
8.3. Specialty Clinics
8.3.1. Specialty Clinics Market, 2018-2030 (USD Million)
8.4. Academic and Research Centers
8.4.1. Academic and Research Centers Market, 2018-2030 (USD Million)
8.5. Others
8.5.1. Others Liquid Biopsy Market, 2018-2030 (USD Million)
Chapter 9. Clinical Application Business Analysis
9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
9.2. Therapy Selection
9.2.1. Therapy Selection Market, 2018-2030 (USD Million)
9.3. Treatment Monitoring
9.3.1. Treatment Monitoring Market, 2018-2030 (USD Million)
9.4. Early Cancer Screening
9.4.1. Early Cancer Screening Market, 2018-2030 (USD Million)
9.5. Recurrence Monitoring
9.5.1. Recurrence Monitoring Market, 2018-2030 (USD Million)
9.6. Others
9.6.1. Others Liquid Biopsy Market, 2018-2030 (USD Million)
Chapter 10. Product Business Analysis
10.1. Liquid Biopsy Market: Product Movement Analysis
10.2. Instruments
10.2.1. Instruments Market, 2018-2030 (USD Million)
10.3. Consumables Kits and Reagents
10.3.1. Consumables Kits and Reagents Market, 2018-2030 (USD Million)
10.4. Software and Services
10.4.1. Software and Services Market, 2018-2030 (USD Million)
Chapter 11. Regional Business Analysis
11.1. Liquid Biopsy Market Share By Region, 2023 & 2030
11.2. North America
11.2.1. North America Liquid biopsy market, 2018-2030 (USD Million)
11.2.2. U.S.
11.2.2.1. Key Country Dynamics
11.2.2.2. Target Disease Prevalence
11.2.2.3. Competitive Scenario
11.2.2.4. Regulatory Framework
11.2.2.5. Reimbursement Scenario
11.2.2.6. U.S. Liquid biopsy market, 2018-2030 (USD Million)
11.2.3. Canada
11.2.3.1. Key Country Dynamics
11.2.3.2. Target Disease Prevalence
11.2.3.3. Competitive Scenario
11.2.3.4. Regulatory Framework
11.2.3.5. Reimbursement Scenario
11.2.3.6. Canada Liquid biopsy market, 2018-2030 (USD Million)
11.3. Europe
11.3.1. Europe Liquid biopsy market, 2018-2030 (USD Million)
11.3.2. Germany
11.3.2.1. Key Country Dynamics
11.3.2.2. Target Disease Prevalence
11.3.2.3. Competitive Scenario
11.3.2.4. Regulatory Framework
11.3.2.5. Reimbursement Scenario
11.3.2.6. Germany Liquid biopsy market, 2018-2030 (USD Million)
11.3.3. UK
11.3.3.1. Key Country Dynamics
11.3.3.2. Target Disease Prevalence
11.3.3.3. Competitive Scenario
11.3.3.4. Regulatory Framework
11.3.3.5. Reimbursement Scenario
11.3.3.6. UK Liquid biopsy market, 2018-2030 (USD Million)
11.3.4. France
11.3.4.1. Key Country Dynamics
11.3.4.2. Target Disease Prevalence
11.3.4.3. Competitive Scenario
11.3.4.4. Regulatory Framework
11.3.4.5. Reimbursement Scenario
11.3.4.6. France Liquid biopsy market, 2018-2030 (USD Million)
11.3.5. Italy
11.3.5.1. Key Country Dynamics
11.3.5.2. Target Disease Prevalence
11.3.5.3. Competitive Scenario
11.3.5.4. Regulatory Framework
11.3.5.5. Reimbursement Scenario
11.3.5.6. Italy Liquid biopsy market, 2018-2030 (USD Million)
11.3.6. Spain
11.3.6.1. Key Country Dynamics
11.3.6.2. Target Disease Prevalence
11.3.6.3. Competitive Scenario
11.3.6.4. Regulatory Framework
11.3.6.5. Reimbursement Scenario
11.3.6.6. Spain Liquid biopsy market, 2018-2030 (USD Million)
11.3.7. Denmark
11.3.7.1. Key Country Dynamics
11.3.7.2. Target Disease Prevalence
11.3.7.3. Competitive Scenario
11.3.7.4. Regulatory Framework
11.3.7.5. Reimbursement Scenario
11.3.7.6. Denmark Liquid biopsy market, 2018-2030 (USD Million)
11.3.8. Sweden
11.3.8.1. Key Country Dynamics
11.3.8.2. Target Disease Prevalence
11.3.8.3. Competitive Scenario
11.3.8.4. Regulatory Framework
11.3.8.5. Reimbursement Scenario
11.3.8.6. Sweden Liquid biopsy market, 2018-2030 (USD Million)
11.3.9. Norway
11.3.9.1. Key Country Dynamics
11.3.9.2. Target Disease Prevalence
11.3.9.3. Competitive Scenario
11.3.9.4. Regulatory Framework
11.3.9.5. Reimbursement Scenario
11.3.9.6. Norway Liquid biopsy market, 2018-2030 (USD Million)
11.4. Asia-Pacific
11.4.1. Asia-Pacific Liquid biopsy market, 2018-2030 (USD Million)
11.4.2. Japan
11.4.2.1. Key Country Dynamics
11.4.2.2. Target Disease Prevalence
11.4.2.3. Competitive Scenario
11.4.2.4. Regulatory Framework
11.4.2.5. Reimbursement Scenario
11.4.2.6. Japan Liquid biopsy market, 2018-2030 (USD Million)
11.4.3. China
11.4.3.1. Key Country Dynamics
11.4.3.2. Target Disease Prevalence
11.4.3.3. Competitive Scenario
11.4.3.4. Regulatory Framework
11.4.3.5. Reimbursement Scenario
11.4.3.6. China Liquid biopsy market, 2018-2030 (USD Million)
11.4.4. India
11.4.4.1. Key Country Dynamics
11.4.4.2. Target Disease Prevalence
11.4.4.3. Competitive Scenario
11.4.4.4. Regulatory Framework
11.4.4.5. Reimbursement Scenario
11.4.4.6. India Liquid biopsy market, 2018-2030 (USD Million)
11.4.5. South Korea
11.4.5.1. Key Country Dynamics
11.4.5.2. Target Disease Prevalence
11.4.5.3. Competitive Scenario
11.4.5.4. Regulatory Framework
11.4.5.5. Reimbursement Scenario
11.4.5.6. South Korea Liquid biopsy market, 2018-2030 (USD Million)
11.4.6. Australia
11.4.6.1. Key Country Dynamics
11.4.6.2. Target Disease Prevalence
11.4.6.3. Competitive Scenario
11.4.6.4. Regulatory Framework
11.4.6.5. Reimbursement Scenario
11.4.6.6. Australia Liquid biopsy market, 2018-2030 (USD Million)
11.4.7. Thailand
11.4.7.1. Key Country Dynamics
11.4.7.2. Target Disease Prevalence
11.4.7.3. Competitive Scenario
11.4.7.4. Regulatory Framework
11.4.7.5. Reimbursement Scenario
11.4.7.6. Thailand Liquid biopsy market, 2018-2030 (USD Million)
11.5. Latin America
11.5.1. Latin America Liquid biopsy market, 2018-2030 (USD Million)
11.5.2. Brazil
11.5.2.1. Key Country Dynamics
11.5.2.2. Target Disease Prevalence
11.5.2.3. Competitive Scenario
11.5.2.4. Regulatory Framework
11.5.2.5. Reimbursement Scenario
11.5.2.6. Brazil Liquid biopsy market, 2018-2030 (USD Million)
11.5.3. Mexico
11.5.3.1. Key Country Dynamics
11.5.3.2. Target Disease Prevalence
11.5.3.3. Competitive Scenario
11.5.3.4. Regulatory Framework
11.5.3.5. Reimbursement Scenario
11.5.3.6. Mexico Liquid biopsy market, 2018-2030 (USD Million)
11.5.4. Argentina
11.5.4.1. Key Country Dynamics
11.5.4.2. Target Disease Prevalence
11.5.4.3. Competitive Scenario
11.5.4.4. Regulatory Framework
11.5.4.5. Reimbursement Scenario
11.5.4.6. Argentina Liquid biopsy market, 2018-2030 (USD Million)
11.6. MEA
11.6.1. MEA Liquid biopsy market, 2018-2030 (USD Million)
11.6.2. South Africa
11.6.2.1. Key Country Dynamics
11.6.2.2. Target Disease Prevalence
11.6.2.3. Competitive Scenario
11.6.2.4. Regulatory Framework
11.6.2.5. Reimbursement Scenario
11.6.2.6. South Africa Liquid biopsy market, 2018-2030 (USD Million)
11.6.3. Saudi Arabia
11.6.3.1. Key Country Dynamics
11.6.3.2. Target Disease Prevalence
11.6.3.3. Competitive Scenario
11.6.3.4. Regulatory Framework
11.6.3.5. Reimbursement Scenario
11.6.3.6. Saudi Arabia Liquid biopsy market, 2018-2030 (USD Million)
11.6.4. UAE
11.6.4.1. Key Country Dynamics
11.6.4.2. Target Disease Prevalence
11.6.4.3. Competitive Scenario
11.6.4.4. Regulatory Framework
11.6.4.5. Reimbursement Scenario
11.6.4.6. UAE Liquid biopsy market, 2018-2030 (USD Million)
11.6.5. Kuwait
11.6.5.1. Key Country Dynamics
11.6.5.2. Target Disease Prevalence
11.6.5.3. Competitive Scenario
11.6.5.4. Regulatory Framework
11.6.5.5. Reimbursement Scenario
11.6.5.6. Kuwait Liquid biopsy market, 2018-2030 (USD Million)
Chapter 12. Competitive Landscape
12.1. Participant’s overview
12.2. Financial performance
12.3. Participant categorization
12.3.1. Market Leaders
12.3.2. Liquid Biopsy Market Share Analysis, 2023
12.3.3. Company Profiles
12.3.3.1. ANGLE plc
12.3.3.1.1. Company Overview
12.3.3.1.2. Financial Performance
12.3.3.1.3. Product Benchmarking
12.3.3.1.4. Strategic Initiatives
12.3.3.2. Oncimmune Holdings PLC
12.3.3.2.1. Company Overview
12.3.3.2.2. Financial Performance
12.3.3.2.3. Product Benchmarking
12.3.3.2.4. Strategic Initiatives
12.3.3.3. Guardant Health
12.3.3.3.1. Company Overview
12.3.3.3.2. Financial Performance
12.3.3.3.3. Product Benchmarking
12.3.3.3.4. Strategic Initiatives
12.3.3.4. Myriad Genetics, Inc.
12.3.3.4.1. Company Overview
12.3.3.4.2. Financial Performance
12.3.3.4.3. Product Benchmarking
12.3.3.4.4. Strategic Initiatives
12.3.3.5. Biocept, Inc.
12.3.3.5.1. Company Overview
12.3.3.5.2. Financial Performance
12.3.3.5.3. Product Benchmarking
12.3.3.5.4. Strategic Initiatives
12.3.3.6. Lucence Health Inc.
12.3.3.6.1. Company Overview
12.3.3.6.2. Financial Performance
12.3.3.6.3. Product Benchmarking
12.3.3.6.4. Strategic Initiatives
12.3.3.7. Freenome Holdings, Inc.
12.3.3.7.1. Company Overview
12.3.3.7.2. Financial Performance
12.3.3.7.3. Product Benchmarking
12.3.3.7.4. Strategic Initiatives
12.3.3.8. F. Hoffmann-La Roche Ltd.
12.3.3.8.1. Company Overview
12.3.3.8.2. Financial Performance
12.3.3.8.3. Product Benchmarking
12.3.3.8.4. Strategic Initiatives
12.3.3.9. QIAGEN
12.3.3.9.1. Company Overview
12.3.3.9.2. Financial Performance
12.3.3.9.3. Product Benchmarking
12.3.3.9.4. Strategic Initiatives
12.3.3.10. Illumina, Inc.
12.3.3.10.1. Company Overview
12.3.3.10.2. Financial Performance
12.3.3.10.3. Product Benchmarking
12.3.3.10.4. Strategic Initiatives
12.3.3.11. Thermo Fisher Scientific, Inc.
12.3.3.11.1. Company Overview
12.3.3.11.2. Financial Performance
12.3.3.11.3. Product Benchmarking
12.3.3.11.4. Strategic Initiatives
12.3.3.12. Epigenomics AG
12.3.3.12.1. Company Overview
12.3.3.12.2. Financial Performance
12.3.3.12.3. Product Benchmarking
12.3.3.12.4. Strategic Initiatives
12.3.4. Strategy Mapping
12.3.4.1. Expansion
12.3.4.2. Acquisition
12.3.4.3. Collaborations
12.3.4.4. Disease Type/Drug Class Launch
12.3.4.5. Partnerships
12.3.4.6. Others
List of Tables
Table 1 List of Tables
Table 2 Global Liquid Biopsy Market, By Region, 2018-2030 (USD Million)
Table 3 Global Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 4 Global Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 5 Global Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 6 Global Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 7 Global Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 8 Global Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 9 Global Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 10 North America Liquid Biopsy Market, By Country, 2018-2030 (USD Million)
Table 11 North America Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 12 North America Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 13 North America Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 14 North America Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 15 North America Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 16 North America Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 17 North America Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 18 U.S. Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 19 U.S. Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 20 U.S. Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 21 U.S. Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 22 U.S. Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 23 U.S. Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 24 U.S. Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 25 Canada Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 26 Canada Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 27 Canada Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 28 Canada Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 29 Canada Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 30 Canada Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 31 Canada Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 32 Europe Liquid Biopsy Market, By Country, 2018-2030 (USD Million)
Table 33 Europe Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 34 Europe Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 35 Europe Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 36 Europe Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 37 Europe Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 38 Europe Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 39 Europe Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 40 UK Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 41 UK Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 42 UK Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 43 UK Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 44 UK Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 45 UK Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 46 UK Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 47 Germany Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 48 Germany Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 49 Germany Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 50 Germany Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 51 Germany Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 52 Germany Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 53 Germany Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 54 France Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 55 France Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 56 France Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 57 France Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 58 France Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 59 France Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 60 France Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 61 Italy Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 62 Italy Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 63 Italy Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 64 Italy Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 65 Italy Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 66 Italy Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 67 Italy Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 68 Spain Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 69 Spain Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 70 Spain Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 71 Spain Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 72 Spain Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 73 Spain Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 74 Spain Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 75 Denmark Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 76 Denmark Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 77 Denmark Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 78 Denmark Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 79 Denmark Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 80 Denmark Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 81 Denmark Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 82 Sweden Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 83 Sweden Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 84 Sweden Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 85 Sweden Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 86 Sweden Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 87 Sweden Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 88 Sweden Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 89 Norway Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 90 Norway Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 91 Norway Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 92 Norway Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 93 Norway Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 94 Norway Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 95 Norway Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 96 Asia-Pacific Liquid Biopsy Market, By Country, 2018-2030 (USD Million)
Table 97 Asia-Pacific Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 98 Asia-Pacific Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 99 Asia-Pacific Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 100 Asia-Pacific Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 101 Asia-Pacific Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 102 Asia-Pacific Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 103 Asia-Pacific Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 104 Japan Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 105 Japan Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 106 Japan Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 107 Japan Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 108 Japan Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 109 Japan Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 110 Japan Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 111 China Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 112 China Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 113 China Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 114 China Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 115 China Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 116 China Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 117 China Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 118 India Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 119 India Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 120 India Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 121 India Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 122 India Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 123 India Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 124 India Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 125 Australia Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 126 Australia Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 127 Australia Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 128 Australia Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 129 Australia Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 130 Australia Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 131 Australia Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 132 South Korea Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 133 South Korea Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 134 South Korea Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 135 South Korea Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 136 South Korea Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 137 South Korea Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 138 South Korea Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 139 Thailand Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 140 Thailand Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 141 Thailand Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 142 Thailand Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 143 Thailand Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 144 Thailand Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 145 Thailand Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 146 Latin America Liquid Biopsy Market, By Country, 2018-2030 (USD Million)
Table 147 Latin America Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 148 Latin America Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 149 Latin America Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 150 Latin America Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 151 Latin America Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 152 Latin America Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 153 Latin America Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 154 Brazil Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 155 Brazil Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 156 Brazil Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 157 Brazil Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 158 Brazil Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 159 Brazil Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 160 Brazil Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 161 Mexico Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 162 Mexico Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 163 Mexico Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 164 Mexico Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 165 Mexico Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 166 Mexico Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 167 Mexico Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 168 Argentina Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 169 Argentina Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 170 Argentina Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 171 Argentina Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 172 Argentina Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 173 Argentina Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 174 Argentina Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 175 Middle East & Africa Liquid Biopsy Market, By Country, 2018-2030 (USD Million)
Table 176 Middle East & Africa Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 177 Middle East & Africa Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 178 Middle East & Africa Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 179 Middle East & Africa Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 180 Middle East & Africa Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 181 Middle East & Africa Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 182 Middle East & Africa Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 183 South Africa Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 184 South Africa Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 185 South Africa Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 186 South Africa Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 187 South Africa Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 188 South Africa Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 189 South Africa Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 190 Saudi Arabia Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 191 Saudi Arabia Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 192 Saudi Arabia Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 193 Saudi Arabia Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 194 Saudi Arabia Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 195 Saudi Arabia Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 196 Saudi Arabia Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 197 UAE Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 198 UAE Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 199 UAE Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 200 UAE Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 201 UAE Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 202 UAE Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 203 UAE Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
Table 204 Kuwait Liquid Biopsy Market, By Sample Type, 2018-2030 (USD Million)
Table 205 Kuwait Liquid Biopsy Market, By Biomarker, 2018-2030 (USD Million)
Table 206 Kuwait Liquid Biopsy Market, By Technology, 2018-2030 (USD Million)
Table 207 Kuwait Liquid Biopsy Market, By Application, 2018-2030 (USD Million)
Table 208 Kuwait Liquid Biopsy Market, By End-use, 2018-2030 (USD Million)
Table 209 Kuwait Liquid Biopsy Market, By Clinical Application, 2018-2030 (USD Million)
Table 210 Kuwait Liquid Biopsy Market, By Product, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Liquid biopsy market segmentation
Figure 8 Market driver relevance analysis (Current & future impact)
Figure 9 Market restraint relevance analysis (Current & future impact)
Figure 10 Market challenge relevance analysis (Current & future impact)
Figure 11 Penetration & growth prospect mapping
Figure 12 SWOT analysis, by factor (political & legal, economic, and technological)
Figure 13 Porter’s five forces analysis
Figure 14 Market penetration vs growth prospect mapping
Figure 15 Liquid biopsy market: Sample Type movement analysis
Figure 16 Blood sample liquid biopsy market, 2018-2030 (USD Million)
Figure 17 Others liquid biopsy market, 2018-2030 (USD Million)
Figure 18 Liquid biopsy market: Biomarker movement analysis
Figure 19 Circulating Tumor Cells (CTCs) liquid biopsy market, 2018-2030 (USD Million)
Figure 20 Circulating Nucleic Acids liquid biopsy market, 2018-2030 (USD Million)
Figure 21 Exosomes/Microvesicles liquid biopsy market, 2018-2030 (USD Million)
Figure 22 Others liquid biopsy market, 2018-2030 (USD Million)
Figure 23 Liquid biopsy market: Technology movement analysis
Figure 24 Multi-gene-parallel analysis (NGS) liquid biopsy market, 2018-2030 (USD Million)
Figure 25 Single gene analysis (PCR Microarrays) liquid biopsy market, 2018-2030 (USD Million)
Figure 26 Liquid biopsy market: Application movement analysis
Figure 27 Cancer liquid biopsy market, 2018-2030 (USD Million)
Figure 28 Lung cancer liquid biopsy market, 2018-2030 (USD Million)
Figure 29 Prostate cancer liquid biopsy market, 2018-2030 (USD Million)
Figure 30 Breast cancer liquid biopsy market, 2018-2030 (USD Million)
Figure 31 Colorectal cancer liquid biopsy market, 2018-2030 (USD Million)
Figure 32 Leukemia liquid biopsy market, 2018-2030 (USD Million)
Figure 33 Gastrointestinal cancer liquid biopsy market, 2018-2030 (USD Million)
Figure 34 Others liquid biopsy market, 2018-2030 (USD Million)
Figure 35 Reproductive Health liquid biopsy market, 2018-2030 (USD Million)
Figure 36 Others liquid biopsy market, 2018-2030 (USD Million)
Figure 37 Liquid biopsy market: End-use movement analysis
Figure 38 Hospitals and Laboratories liquid biopsy market, 2018-2030 (USD Million)
Figure 39 Specialty clinics liquid biopsy market, 2018-2030 (USD Million)
Figure 40 Academic and research centers liquid biopsy market, 2018-2030 (USD Million)
Figure 41 Others liquid biopsy market, 2018-2030 (USD Million)
Figure 42 Liquid biopsy market: Clinical application movement analysis
Figure 43 Therapy selection liquid biopsy market, 2018-2030 (USD Million)
Figure 44 Treatment monitoring liquid biopsy market, 2018-2030 (USD Million)
Figure 45 Early cancer screening liquid biopsy market, 2018-2030 (USD Million)
Figure 46 Recurrence monitoring liquid biopsy market, 2018-2030 (USD Million)
Figure 47 Others liquid biopsy market, 2018-2030 (USD Million)
Figure 48 Liquid biopsy market: Product movement analysis
Figure 49 Instruments liquid biopsy market, 2018-2030 (USD Million)
Figure 50 Consumables kits and reagents liquid biopsy market, 2018-2030 (USD Million)
Figure 51 Software and Services liquid biopsy market, 2018-2030 (USD Million)
Figure 52 Regional marketplace: Key takeaways
Figure 53 Regional outlook, 2018 & 2030
Figure 54 North America liquid biopsy market, 2018-2030 (USD Million)
Figure 55 U.S. liquid biopsy market, 2018-2030 (USD Million)
Figure 56 Canada liquid biopsy market, 2018-2030 (USD Million)
Figure 57 Europe liquid biopsy market, 2018-2030 (USD Million)
Figure 58 UK liquid biopsy market, 2018-2030 (USD Million)
Figure 59 Germany liquid biopsy market, 2018-2030 (USD Million)
Figure 60 Italy liquid biopsy market, 2018-2030 (USD Million)
Figure 61 Spain liquid biopsy market, 2018-2030 (USD Million)
Figure 62 France liquid biopsy market, 2018-2030 (USD Million)
Figure 63 Denmark liquid biopsy market, 2018-2030 (USD Million)
Figure 64 Sweden liquid biopsy market, 2018-2030 (USD Million)
Figure 65 Norway liquid biopsy market, 2018-2030 (USD Million)
Figure 66 Asia-Pacific liquid biopsy market, 2018-2030 (USD Million)
Figure 67 Japan liquid biopsy market, 2018-2030 (USD Million)
Figure 68 China liquid biopsy market, 2018-2030 (USD Million)
Figure 69 India liquid biopsy market, 2018-2030 (USD Million)
Figure 70 Australia liquid biopsy market, 2018-2030 (USD Million)
Figure 71 South Korea liquid biopsy market, 2018-2030 (USD Million)
Figure 72 Thailand liquid biopsy market, 2018-2030 (USD Million)
Figure 73 Latin America liquid biopsy market, 2018-2030 (USD Million)
Figure 74 Brazil liquid biopsy market, 2018-2030 (USD Million)
Figure 75 Mexico liquid biopsy market, 2018-2030 (USD Million)
Figure 76 Argentina liquid biopsy market, 2018-2030 (USD Million)
Figure 77 MEA liquid biopsy market, 2018-2030 (USD Million)
Figure 78 South Africa liquid biopsy market, 2018-2030 (USD Million)
Figure 79 Saudi Arabia liquid biopsy market, 2018-2030 (USD Million)
Figure 80 UAE liquid biopsy market, 2018-2030 (USD Million)
Figure 81 Kuwait liquid biopsy market, 2018-2030 (USD Million)

Companies Mentioned

  • ANGLE plc
  • Oncimmune Holdings PLC
  • Guardant Health
  • Myriad Genetics, Inc.
  • Biocept, Inc.
  • Lucence Health Inc.
  • Freenome Holdings, Inc.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Epigenomics AG

Methodology

Loading
LOADING...